Andarine

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Andarine has no FDA-approved indication and is not a scheduled controlled substance under the Controlled Substances Act. The FDA considers it an unapproved new drug; marketing or sale for human use, including as a dietary supplement or performance enhancer, is unlawful. It is not listed in the FDA 503A/503B compounding bulk drug substances lists. Research-use-only (RUO) supply for laboratory purposes occupies a regulatory grey area but does not confer authorisation for clinical or human use.

Confirmed high-severity market-integrity event (enforcement / recall / counterfeit)

Transparent blend · bci-1.0 · never paid-placement

Primary name

Andarine

Origin

Synthetic non-steroidal small molecule developed by GTX, Inc. in collaboration with the University of Tennessee in the early 2000s as an investigational treatment for muscle wasting, osteoporosis, and benign prostatic hyperplasia. Development was discontinued after preclinical and early-phase findings of reversible visual disturbances linked to off-target binding in ocular tissue.

Registry IDs

PubChem CID

9824562

CAS

401900-40-1

InChIKey

YVXVTLGIDOACBJ-SFHVURJKSA-N

DrugBank

DB07423

ChEMBL

CHEMBL125236

Molecular formula

C19H18F3N3O6

Molar mass

441.4 g/mol

Monoisotopic

441.11476979 Da

InChIKey

YVXVTLGIDOACBJ-SFHVURJKSA-N

Appearance

White to off-white crystalline powder

Solubility

Practically insoluble in water; soluble in DMSO (~10–20 mg/mL), ethanol, and pol…

Sequence not available in current seed.

Stability: Generally stable as dry powder; degrades under prolonged exposure to light, moisture, and high temperatures. Reconstituted solutions should be used promptly or

Vial sizes

null mg

Purity grades

≥98% / ≥99%

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Andarine binds to the androgen receptor (AR) with high affinity and acts as a tissue-selective partial agonist, preferentially activating AR-dependent transcription in skeletal muscle and bone while producing comparatively limited stimulation in the prostate and seminal vesicles
• Its non-steroidal arylpropionamide scaffold allows differential coactivator recruitment relative to endogenous androgens, which underlies tissue selectivity
• In preclinical rodent models, andarine preserved lean mass and bone mineral density in states of androgen deficiency through this mechanism
• Emerging in-vitro work suggests additional anti-proliferative effects in certain cancer cell lines, mediated at least partly through suppression of PI3K/AKT/mTOR signalling, though this has not been validated in vivo (PMID 36990257, PMID 38997069)

Pharmacokinetics (ADME)

Half-life

Approximately 200–320 minutes (rat; ~3–5 h) — no published human PK data

Clearance

Moderate systemic clearance in rat models; volume of distribution approximately 0.45 L/kg (rat)

PK–PD note: Oral bioavailability appears dose-dependent in rodent studies (PMID 15204699, not in gathered list — animal data only). No human PK study has been published; andarine did not advance to completed Phas…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Solomon ZJ, et al. Selective Androgen Receptor Modulators (SARMs) - Current Knowledge and Clinical Applications. Sex Med Rev. 2019;7(1):84-94. — Narrative literature review of SARMs including andarine; MEDLINE search methodology
• Wikipedia: Andarine (developmental code GTx-007, S-4) — Aggregator summary citing primary pharmacology literature; confirms phase 1 completion 2003 and discontinuation due to visual disturbances
• Gao W, et al. Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats. Endocrinology. 2004. — Primary preclinical study characterizing S-4 full agonist activity in skeletal muscle, bone, pituitary
• MedChemExpress: GTx-007 (S-4) product data sheet — Vendor aggregator; Ki 4 nM binding affinity and partial agonist classification

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

The most distinctive adverse effect reported from early preclinical and limited human exposure is a reversible visual disturbance characterised by a yellow or green tint to vision and impaired night vision, attributed to partial agonism at androgen receptors in retinal or ocular …

WADA status

Prohibited in-competition and out-of-competition under WADA Prohibited List Section S1.2 (Other Anabolic Agents). Andarine has appeared on the list since approx…

Dominant research route: PO (oral)

Dogs and rats (PK/bioavailability); humans (Phase I safety/tolerability, n=86 healthy volunteers)

Bioavailability: In dogs, oral bioavailability was ~91% at pharmacologically relevant doses with linear kinetics; dose-dependent oral bioavailability was observed (Perera et al., 2006).

Andarine is characterized as an orally active partial androgen receptor agonist. Three Phase I trials (1a, 1b, 1c) were completed in 2003 in 86 healthy male and female volunteers for cachexia; Phase 2 was planned for 2004 but development was discontinued, reportedly due to visual disturbances.

Dogs (PK reference)

Bioavailability: IV bolus (3 or 10 mg/kg) in dogs yielded linear pharmacokinetics with a mean clearance of 4.6 ml/min/kg and a mean half-life of about 200 min; IV arm served as reference for oral bioavailability determination.

IV administration was used only as the reference route in the dog pharmacokinetic study to calculate oral bioavailability (F). No human IV data located.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $0.039 · median $0.048 · p75 $0.063 · 7 researched vendors

Legit, COA-backed band: $0.032–$0.065/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$0

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Single black-market sample (Thevis 2009): ~90% S-4 with ~10% synthetic impurity from poor purification; no independent multi-batch purity range for andarine was retrieved.

Independent labs cited for this compound

No FDA recall or market withdrawal specifically naming an Andarine/S-4 product was found in the retrieved sources; FDA enforcement against andarine has taken the form of warning letters and import detention rather than Class I/II recalls. none found.

Buyer red-flag checklist

• Marketed as 'for research use only' to circumvent drug regulation; FDA states this designation is invalid if products are capsulated, formulated for oral administration, or dosed for human consumption.
• Black-market andarine products have been misdeclared as 'green tea extracts' and 'face moisturizer' (Thevis 2009).
• ~48% of internet SARM products contained no detectable SARM and 59% had label-amount mismatches (JAMA 2017).
• Andarine is on the WADA Prohibited List (S1.2) since 2008; any positive is a doping violation.
• FDA has pursued criminal actions against SARM distributors (e.g., SPP/Science Production Plus conviction for smuggling SARMs from China).
• Clinical development of andarine was discontinued, attributed in part to visual side effects (blurred/yellow-tinted vision, light-adaptation difficulty).
• FDA warns SARMs may cause life-threatening reactions including liver toxicity and elevated heart attack/stroke risk.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Aggregate SARM-class figure (not andarine-specific): in the JAMA 2017 study, 48% of 44 internet products marketed as SARMs (Ostarine, LGD-4033, or Andarine) contained no detectable SARM; 59% had amounts differing from label. A 2025 Slovak study found ~44% of declared-SARM supplements did not contain the declared compound, with andarine not confirmed in 1 declared sample. No Janoshik/MZ Biolabs/Finnrick andarine-specific aggregate was retrieved.

• Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. SARMs (including andarine/S-4) marketed for human use fall under this alert as unapproved new drugs; FDA field divisions may detain identified products from firms on the Red List without physical examination.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Prohibited at all times (in- and out-of-competition) under S1.2 'Other Anabolic Agents'; andarine explicitly named on the 2025 WADA Prohibited List. Listed since 2008.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• self-selection bias — only enthusiasts post logs
• anecdotal dosing without bloodwork verification
• source-affiliated posters in r/sarmssourcetalk
• broscience phenomenon amplified via social media
• no controlled dosing or blinding
• survivorship bias — negative outcomes underreported

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Non-steroidal SARM (GTx-007/S-4) that selectively activates androgen receptors in muscle and bone; never approved; development halted after vision adverse effects. Approximately 40 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Not FDA-approved; sold solely for research use. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet